BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Bioinformatics Software | QIAGEN Digital Insights - ECPv6.15.17.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://staging.digitalinsights.supremeclients.com
X-WR-CALDESC:Events for Bioinformatics Software | QIAGEN Digital Insights
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Halifax
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20220313T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20221106T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20230312T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20231105T050000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0400
TZOFFSETTO:-0300
TZNAME:ADT
DTSTART:20240310T060000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0300
TZOFFSETTO:-0400
TZNAME:AST
DTSTART:20241103T050000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20240310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20241103T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20231114
DTEND;VALUE=DATE:20231119
DTSTAMP:20260410T193312
CREATED:20231030T164514Z
LAST-MODIFIED:20241024T182948Z
UID:10000699-1699920000-1700351999@staging.digitalinsights.supremeclients.com
SUMMARY:AMP 2023
DESCRIPTION:AMP is the leading organization in the field of molecular diagnostics\, and our annual meeting is widely considered the “premier gathering” of molecular professionals. As always\, we will explore how cutting-edge technology and developments in molecular testing continue to have a major and direct impact on patient care. The AMP 2023 Program Committee is planning an impressive program to spark dialogue and engagement amongst attendees and exhibitors from around the world\, and we look forward to welcoming you to discuss the latest in molecular diagnostics and network with friends and colleagues.
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/amp-2023/
LOCATION:Salt Lake City\, Salt Lake City\, UT\, United States
CATEGORIES:Clinical,Event
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_9993_GEN_gi1134578085.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/Halifax:20231116T130000
DTEND;TZID=America/Halifax:20231116T140000
DTSTAMP:20260410T193312
CREATED:20231026T115707Z
LAST-MODIFIED:20241024T182947Z
UID:10000697-1700139600-1700143200@staging.digitalinsights.supremeclients.com
SUMMARY:How clinical labs can confidently assess cancer-associated variants with real-world data and expert-curated genomic evidence
DESCRIPTION:Across various stages of the clinical oncology workflow\, from panel design to genomic testing and molecular tumor boards\, the identification and validation of actionable genomic alterations is critical. The advent of next-generation sequencing (NGS) has led to an exponential increase in the number of variants detected in tumor testing\, posing a challenge for clinical cancer genetics professionals seeking to confidently discern clinically relevant mutations that can guide patient care decisions.\n\nJoin Dr. Umadevi Thirumurthi\, Associate Director of Global Product Management for Oncology at QIAGEN Digital Insights as she discusses how the Human Somatic Mutation Database (HSMD)\, an expert-curated somatic variant database\, can enhance your clinical NGS workflow.\n\nAttendees will learn how HSMD:\n\nCan be used to design targeted panels\, streamline somatic variant analysis\, and support molecular tumor board decisions;\nProvides access to data from over 419\,00 real-world oncology cases and human-certified expert curation\nEnables users to effortlessly explore mutational characteristics across genes\, synthesize critical information from drug labels and professional guidelines\, investigate ongoing clinical trials\, and access comprehensive annotations for each observed variant
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/how-clinical-labs-can-confidently-assess-cancer-associated-variants-with-real-world-data-and-expert-curated-genomic-evidence/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Clinical,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1144_4_QDI_QCI_HSMD_GI1227547264_Full-resolution_59165-scaled-1.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20231116T130000
DTEND;TZID=America/New_York:20231116T143000
DTSTAMP:20260410T193312
CREATED:20231012T165109Z
LAST-MODIFIED:20241024T182944Z
UID:10000694-1700139600-1700145000@staging.digitalinsights.supremeclients.com
SUMMARY:Making discoveries from public data (GEO\, SRA and more) using QIAGEN Ingenuity Pathway Analysis
DESCRIPTION:You requested it\, and we’re here to deliver. We’re excited to offer you comprehensive training on how to effectively use sample-level public data and metadata from sources like GEO\, SRA\, TCGA\, GTEx\, Blueprint\, CCLE and other sources through QIAGEN Ingenuity Pathway Analysis (IPA) and the IPA Analysis Match Explorer feature. Your trainer will walk you through use cases in related to biomarker discovery\, drug target investigation\, studying survival in custom patient cohorts\, multi-gene correlation and more. Note: The word “condition” below refers to different diseases\, disease subtypes\, treatments\, cell types\, cell lines and more.  \nIn this training\, we’ll cover topics such as: • How is a gene of interest expressed across different conditions? • Is there a correlation in expression for two genes or biomarkers of user interest for a given condition? • For a given condition of interest\, can we derive a list of genes (for example\, genes specific to a disease\, treatment or cell type)? • Can we generate custom cohorts of patients (for example\, TP53 wt vs mutant or PDCD1 high vs low expression) and then generate survival curves representing those cohorts? Can we generate p-value to see if there is a significant difference? • Recent update: Can we detect the expression of a gene in different cell types from single-cell data? 
URL:https://staging.digitalinsights.supremeclients.com/webinars-and-events/making-discoveries-from-public-data-geo-sra-and-more-using-qiagen-ingenuity-pathway-analysis/
LOCATION:Virtual - Americas - EST\, United States
CATEGORIES:Discovery,Webinar
ATTACH;FMTTYPE=image/jpeg:https://staging.digitalinsights.supremeclients.com/wp-content/uploads/2024/05/S_1052_1_QDI_OmicSoft_16x9.jpg
END:VEVENT
END:VCALENDAR